The First Psilocybin-Class Phase 3 Win Was an Add-On, Not a Replacement
A psilocybin-class drug has won a Phase 3 trial in depression for the first time. Helus Pharma reported topline results from its APPROACH study on November 16. Psychedelic Alpha broke the news that morning.
Patients taking HLP003 dropped 19.5 points on the standard depression scale by week 6. Placebo dropped 11.9. That is a 7.6 point separation, and half the treated group was in remission.
The number that matters more to a clinic is none of those. Every patient in the trial stayed on the antidepressant they walked in with.
Approval is years out. The staffing math starts the moment a protocol like this one gets a label. The HealingMaps GPO is the first built for the ketamine industry. Members get 15 to 20 percent off malpractice and liability premiums, 40 percent or more off medical supplies, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free and carries no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| What happened | APPROACH, the first of two pivotal Phase 3 trials, met its primary endpoint |
| The drug | HLP003, a deuterated psilocin analog. Two 16 mg doses, three weeks apart |
| The design | Adjunctive. Both arms continued their existing antidepressant throughout |
| Primary result | MADRS fell 19.5 points vs 11.9 on placebo at week 6. A 7.6 point gap |
| Remission | 50.9% of treated patients vs 18.2% on placebo at week 6 |
| Speed | Separation at Day 2, two days after the first dose |
| The staffing line | The registry lists manualized psychological support by facilitators as an intervention |
| Who this company is | Helus Pharma was Cybin until September 23, 2026. HLP003 was CYB003 |
| Not yet | Topline release only. No paper, no peer review, and the second trial reads out in late 2027 |
What the trial actually reported
APPROACH randomized 222 adults with moderate to severe major depressive disorder, 112 to drug and 110 to placebo. Baseline depression scores sat around 33, which is solidly in the severe range.
The primary endpoint was a 7.6 point placebo-adjusted drop on the Montgomery-Asberg scale at week 6. The company reports it at p below 0.0001. Response was 56.3 percent against 28.2. Remission was 50.9 against 18.2.
The effect showed up fast and held. By Day 2 the gap was 5.0 points, with an effect size of 0.438. At week 12 it was still 7.0 points.
The trial registry lists the study as quadruple masked. Patients, care providers, investigators and outcome assessors were all blinded. That is a stronger design than the release itself claims.
Adjunctive is the whole story
Compass describes its own pivotal trial of COMP360 as single dose monotherapy. Its filing is for treatment-resistant depression, a narrower population defined by having already failed two or more antidepressants.
Helus went the other direction. It kept patients on their medication and added two dosing sessions on top. The population is major depressive disorder with an inadequate response, not treatment resistance.
For a clinic that matters more than the effect size. An adjunctive protocol means no washout and no taper off a working drug. There are no discontinuation symptoms to manage before anybody gets dosed.
That is operationally close to what a ketamine practice already does. Most ketamine patients arrive on something and stay on it.
The intervention list includes staffing
The trial registry lists three interventions, not one. HLP003, placebo, and manualized psychological support delivered by facilitators.
That is the line to read twice. The drug was not tested as a pill handed to a patient. It was tested inside a support protocol with trained people running it.
Our own tally of session length put this compound at four to six hours of chair time. Today’s release says nothing to change that, and nothing about how many facilitator hours the protocol consumes.
Those are the two numbers that decide whether a room is profitable. Neither one moved today. We tracked that race in our look at how hard every company is working to shorten the session.
We flagged this drug before, and the flag held
In August we wrote that Helus had described HLP003 results from only seven participants at twelve month follow up. Five of the seven were in remission. We said seven people is not data.
This is the 222 person version of that claim, and it landed. Remission came in at 50.9 percent rather than 71. That is what usually happens when a small open-label signal meets a placebo arm.
Worth saying plainly: the caution was right and the drug still worked.
What is not in this announcement
There were three treatment-related serious adverse events. The release does not say what they were. That is the single most important missing detail for anyone who would eventually run this protocol.
There is also no publication. The release identifies itself as a designated news release under an active shelf prospectus. The full data has not been peer reviewed or presented.
APPROACH is one of two pivotal trials. EMBRACE is still enrolling and Helus expects topline results in the fourth quarter of 2027. A long-term extension study runs alongside it.
And psilocin is still Schedule I. Compass has said rescheduling has to happen before commercialization. We covered that gate when Compass completed the first psilocybin NDA.
Where this leaves the field
Three psilocybin programs are now in Phase 3 or at the agency. None is chasing the same patient.
| Program | Company | Indication | How it is given |
|---|---|---|---|
| COMP360 | Compass Pathways | Treatment-resistant depression | Company calls its pivotal trial single dose monotherapy |
| Psilocybin | Usona Institute | Major depressive disorder | Phase 3 of 238 adults. NDA reported, not confirmed |
| HLP003 | Helus Pharma | Major depressive disorder | Adjunctive. Two 16 mg doses on top of an antidepressant |
Those distinctions decide referral patterns more than any efficacy number will. We laid out why in the two front-runners are not chasing the same patients.
Patients looking for supervised care today can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not medical or investment advice. HLP003 is investigational and is not approved by the FDA. Figures come from the company’s topline press release and the public trial registry, and have not been peer reviewed.
